Primary Outcome Measures Document the feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy® device To demonstrate the safety of intrapleural administration of the locally manufactured ACT product plus Interleukin 2 (IL-2) to study patients Secondary Outcome Measures To document changes in the pleural[…]
Pleural Mesothelioma
Opdivo and Yervoy Before and After Surgery and a New Blood Test are Improving Mesothelioma Treatment
Researchers are reporting promising results for people with mesothelioma who can have surgery. One researcher tested immunotherapy before and after surgery while the other researcher studied a blood test that helps doctors detect mesothelioma earlier than scans. Doctors at several cancer centers, including Johns Hopkins, ran an early clinical trial[…]
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
Primary Outcome Measures Disease-related Symptom Burden 3 Months After Partial Pleurectomy (Surgery) Secondary Outcome Measures Quality of Life of Study Participants Who Have Undergone Partial Pleurectomy (Surgery) Rate of Complications after Partial Pleurectomy (Surgery) Time to Resumption of Systemic Therapy Overall Survival of Study Participants Who Have Undergone Partial Pleurectomy[…]
Mesothelioma Diagnosis
Mesothelioma is a rare and hard to diagnose cancer. There are many challenges patients and caregivers must face once someone is diagnosed with mesothelioma. There are expert guidelines that were recently updated by the International Mesothelioma Interest group. The group provides insights into mesothelioma’s diagnosis, which is incredibly valuable for[…]
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
Primary Outcome Measures ORR Inclusion Criteria Subjects must provide informed consent prior to initiating any study-specific procedures. Male or female subjects aged ≥18 and ≤75 years. Histologically/cytologically confirmed malignant mesothelioma (MM), including malignant pleural mesothelioma (PM) and malignant peritoneal mesothelioma (PeM). Subjects with MM unsuitable for radical resection and/or radiotherapy[…]
Empyema Challenges After Pleural Mesothelioma Surgery
Pleural mesothelioma, a cancer linked to asbestos exposure, is very tough to treat. Surgery is one part of multimodal therapy that aims to remove as much cancer as possible. Surgery is a very useful tool in the treatment of mesothelioma, but after surgery, complications can occur. One complication can be[…]
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study (NECIM)
Primary Outcome Measures To assess the percentage of successful completion of a neoadjuvant double chemotherapy / double immunotherapy regimen followed by surgery in a selected group of T2-T3 (according to TNM 9) patients with pleural mesothelioma. Secondary Outcome Measures Toxicity of the neoadjuvant double chemotherapy / double immunotherapy regimen and[…]
New Clinical Trial is Testing CAR-T Cell Therapy for Mesothelioma and Other Hard to Treat Tumors
A new clinical trial that launched this month is testing a new immunotherapy regimen that could offer hope to people with mesothelioma and other hard to treat cancers. It will be examining an experimental treatment that utilizes CAR-T cells, an immune cell engineered to find and attack cancer cells. The[…]
An International Study on Pediatric Patients With Rare Tumors. (PARTNER)
Primary Outcome Measures Epidemiology Use of International Recommendations Survival of children and adolescents (0-18 years) affected by Very Rare Tumors Inclusion Criteria Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. Written informed consent from the patient and/or[…]
Immunotherapy Benefits and Drawbacks for Treating Mesothelioma
Mesothelioma is a rare and aggressive cancer that creates multiple challenges for patients and caregivers. Immune checkpoint inhibitors have recently shown promise to bring hope to people suffering from this devastating cancer. New data from Australia, however, is questioning their effectiveness and safety. Patients and caregivers must understand immunotherapy and[…]
Skip to content